Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy

Prostate

Volumn 73, Issue 3, 2013, Pages 250-260

  Grytli, Helene Hartvedt ^a   Fagerland, Morten Wang ^a   Taskén, Kristin Austlid ^a,b   Fosså, Sophie D ^a,b   Håheim, Lise Lund ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

beta adrenergic receptor antagonist; epidemiology; Norway; Oslo II study; prospective cohort

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DIABETES MELLITUS; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SMOKING;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANDROGEN ANTAGONISTS; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NORWAY; PROSTATIC NEOPLASMS; REGISTRIES; REGRESSION ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84872800402     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22564     Document Type: Article

References (31)

1. Sharifi N, McPhaul MJ, Auchus RJ,. " Getting from here to there"-mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer. J Investig Med 2010; 58 (8): 938-944.
2. Merkle D, Hoffmann R,. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor. Cell Signal 2011; 23 (3): 507-515.
3. Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S, Chinnaiyan AM,. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007; 12 (5): 419-431.
4. Palm D, Lang K, Niggemann B, Drell TL, Masur K, Zaenker KS, Entschladen F,. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006; 118 (11): 2744-2749.
5. Cole SW, Sood AK,. Molecular Pathways: Beta-adrenergic signaling pathways in cancer. Clin Cancer Res 2012; 18 (5): 1201-1206.
6. Friedman GD, Udaltsova N, Habel LA,. Norepinephrine antagonists and cancer risk. Int J Cancer 2011; 128 (3): 737-738.
7. Perron L, Bairati I, Harel F, Meyer F,. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004; 15 (6): 535-541.
8. Assimes TL, Elstein E, Langleben A, Suissa S,. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf 2008; 17 (11): 1039-1049.
9. Hole DJ, Hawthorne VM, Isles CG, McGhee SM, Robertson JW, Gillis CR, Wapshaw JA, Lever AF,. Incidence of and mortality from cancer in hypertensive patients. BMJ 1993; 306 (6878): 609-611.
10. Rodriguez C, Jacobs EJ, Deka A, Patel AV, Bain EB, Thun MJ, Calle EE,. Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 2009; 20 (5): 671-679.
11. Ronquist G, Rodriguez LA, Ruigomez A, Johansson S, Wallander MA, Frithz G, Svardsudd K,. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004; 58 (1): 50-56.
12. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, Warshauer ME, Shapiro S,. Calcium channel blockers and the risk of cancer. JAMA 1998; 279 (13): 1000-1004.
13. Kvissel AK, Ramberg H, Eide T, Svindland A, Skalhegg BS, Tasken KA,. Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Cell Signal 2007; 19 (2): 401-409.
14. Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Tasken KA,. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate 2008; 68 (10): 1133-1142.
15. Shah SM, Carey IM, Owen CG, Harris T, Dewilde S, Cook DG,. Does beta-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 2011; 72 (1): 157-161.
16. Leren P, Askevold EM, Foss OP, Froili A, Grymyr D, Helgeland A, Hjermann I, Holme I, Lund-Larsen PG, Norum KR,. The Oslo study. Cardiovascular disease in middle-aged and young Oslo men. Acta Med Scand Suppl 1975; 588: 1-38.
17. Lund HL, Lund Larsen PG, Sogaard AJ, Holme I,. Risk factors associated with body mass index increase in men at 28 years follow-up. QJM 2006; 99 (10): 665-671.
18. Hernes E, Kyrdalen A, Kvale R, Hem E, Klepp O, Axcrona K, Fosså SD,. Initial management of prostate cancer: First year experience with the Norwegian National Prostate Cancer Registry. BJU Int 2010; 105 (6): 805-811.
19. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L,. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen-deprivation therapy. Cancer Res 2012; 72 (2): 527-536.
20. Powe DG, Entschladen F,. Targeted therapies: Using beta-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 2011; 8 (9): 511-512.
21. De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, Geppetti P,. Treatment with beta-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011; 171 (8): 779-781.
22. Lemeshow S, Sorensen HT, Phillips G, Yang EV, Antonsen S, Riis AH, Lesinski GB, Jackson R, Glaser R,. beta-Blockers and survival among Danish patients with malignant melanoma: A population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20 (10): 2273-2279.
23. Martin RM, Vatten L, Gunnell D, Romundstad P,. Blood pressure and risk of prostate cancer: Cohort Norway (CONOR). Cancer Causes Control 2010; 21 (3): 463-472.
24. Stocks T, Hergens MP, Englund A, Ye W, Stattin P,. Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. Int J Cancer 2010; 127 (7): 1660-1668.
25. Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, Moller B,. Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009; 45 (7): 1218-1231.
26. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Motte N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F,. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59 (1): 61-71.
27. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A,. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59 (4): 572-583.
28. Hsing AW, Sakoda LC,. Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86 (3): 843-857.
29. Kang J, Chen MH, Zhang Y, Moran BJ, Dosoretz DE, Katin MJ, Braccioforte MH, Salenius SA, D'Amico AV,. Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82 (3): 463-467.
30. Young-McCaughan S,. Potential for prostate cancer prevention through physical activity. World J Urol 2012; 30 (2): 167-179.
31. Reiter MJ,. Cardiovascular drug class specificity: Beta-blockers. Prog Cardiovasc Dis 2004; 47 (1): 11-33.